Physician profile
Tammy K Pope
NPI 1407810062
$1,028.51
in general payments reported to CMS, 2019-2025
19 companies · $204 in 2025
The $204 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $31.96 · 2021: $110 · 2022: $170 · 2023: $267 · 2024: $246 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $716.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $214.78 | 2020-2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $188.30 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Cardiomems |
| Glaxosmithkline, LLC. | $113.27 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $99.48 | 2023-2025 | Wegovy, Saxenda, Rybelsus |
| Abbvie INC. | $70.13 | 2022-2024 | |
| Idorsia Pharmaceuticals US INC | $53.93 | 2022-2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $44.04 | 2025 | Airsupra |
| Pfizer INC. | $43.71 | 2022-2024 | |
| Currax Pharmaceuticals LLC | $28.60 | 2023-2024 | Onzetra Xsail, Contrave, Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.47 | 2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $19.94 | 2025 | Rexulti |
| Viatris Specialty LLC | $19.38 | 2025 | Yupelri |
| Exact Sciences Corporation | $17.38 | 2023 | Cologuard Collection Kit |
| Shield Therapeutics INC | $16.81 | 2023 | Accrufer |
| Scynexis, INC. | $16.25 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $15.63 | 2024 | Auvelity |
| Nevro Corp. | $14.63 | 2024 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.45 | 2023 | Xifaxan, Trulance |
| Biodelivery Sciences International, INC. | $12.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Pope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.